Skip to Content

Press Releases

Date Title and Summary Additional Formats
Dec 29, 2023
Glass Lewis Recommendation Emphasizes Strong Strategic Rationale and Thorough Process   ISS Reiterates Recommendation Following Public Commentary Recommendations Reiterate that Value Maximizing Transaction Is in the Best Interests of Stockholders; Board Urges Stockholders to Vote "FOR" the
Dec 29, 2023
Continues to Recommend Stockholders Vote "FOR" Pending Merger ISS has Dismissed Madryn's Misleading Claims and Reaffirms that Stockholders Vote "FOR" the Merger   BOULDER, Colo., Dec. 29, 2023 /PRNewswire/ -- SomaLogic, Inc. (Nasdaq:  SLGC ) ("the Company"), a leader in proteomics technology, today
Dec 22, 2023
SOUTH SAN FRANCISCO, Calif. , Dec. 22, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose –  Unleashing tools to accelerate breakthroughs in human health - today announced that leading independent proxy advisory firm Institutional Shareholder Services (“ISS”)
Dec 22, 2023
  Company Urges Stockholders to Vote “FOR” Value Maximizing Transaction at Upcoming Special Meeting   BOULDER, Colo., Dec. 22, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that Institutional Shareholder Services (“ISS”) has recommended that SomaLogic
Dec 21, 2023
Combination Builds Scale and Accelerates Path to Profitability, Unlocking Significant Potential Value for SomaLogic Stockholders Madryn’s Concerns are Not Based on Facts, and Madryn Selectively Ignores Risks in a Standalone Strategy and Potential Benefits of the Merger Urges Stockholders to Vote
Dec 04, 2023
SOUTH SAN FRANCISCO, Calif. and BOULDER, Colo. , Dec. 04, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – and SomaLogic, Inc. (Nasdaq: SLGC), a leader in data-driven proteomics technology, today
Nov 07, 2023
Year-to-date revenue growth, gross margin expansion and operating expense reduction are testament to continued execution against financial objectives Planned merger with SomaLogic activates strategic M&A thesis SOUTH SAN FRANCISCO, Calif. , Nov. 07, 2023 (GLOBE NEWSWIRE) -- BioTools Inc.
Nov 02, 2023
SOUTH SAN FRANCISCO, Calif. , Nov. 02, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose –  Unleashing tools to accelerate breakthroughs in human health – today announced that President and Chief Executive Officer Michael Egholm , PhD, will give a presentation
Oct 25, 2023
SOUTH SAN FRANCISCO, Calif. , Oct. 25, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose –  Unleashing tools to accelerate breakthroughs in human health – today announced that it will report third quarter 2023 financial results on Tuesday, November 7, 2023,
Oct 04, 2023
Activates Standard BioTools’ strategy to unlock value in underserved portion of $100 billion industry Establishes leading platform of multi-omic technologies with the highest throughput and highest data quality to power clinical research insights Expands commercial reach with substantial